Tvardi Therapeutics(TVRD.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Tvardi Therapeutics
TVRD.US
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
5.011 T
TVRD.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases

    Tvardi Therapeutics Inc. has unveiled a corporate presentation detailing its progress in developing STAT3 inhibitors for fibrosis-driven diseases and cancers. The presentation highlights successful target engagement and disease modification in animal models, along with reductions in fibrosis and inflammation in clinical studies. The lead program, TTI-101, is under evaluation for idiopathic pulmonary fibrosis and hepatocellular carcinoma, with more data expected soon. Additionally, TTI-109, a prodrug in Phase 1 trials, aims to improve STAT3 inhibition delivery and tolerability.

    Reuters·
    US
    TVRD
    +4.79%
    Reuters·
    US
    TVRD
    +4.79%

    Tvardi Therapeutics to present new data from Phase 2 REVERT IPF Clinical Trial at J.P. Morgan Healthcare Conference.

    Tvardi Therapeutics will present new findings from its Phase 2 REVERT IPF clinical trial of TTI-101 at the J.P. Morgan Healthcare Conference. The trial evaluates TTI-101's effectiveness in treating idiopathic pulmonary fibrosis (IPF), showcasing significant data on the drug's efficacy and safety. This presentation aims to provide insights into TTI-101's potential impact on managing IPF, offering attendees the latest results and implications for patients.

    Unusual Whales·
    US
    TVRD
    +4.79%
    Unusual Whales·
    US
    TVRD
    +4.79%

    Tvardi Therapeutics Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% Placebo

    Tvardi Therapeutics Inc :TVARDI THERAPEUTICS INC - TTI-101 SHOWS 9.4% FIBROSIS SCORE DECREASE VERSUS 2.4% PLACEBOTVARDI THERAPEUTICS INC - TOPLINE HEALTHY VOLUNTEER DATA FROM PHASE 1 STUDY OF NEXT-GENERATION STAT3 INHIBITOR, TTI-109, ON TRACK FOR H1 2026

    Reuters·
    US
    TVRD
    +4.79%
    Reuters·
    US
    TVRD
    +4.79%

    Tvardi Therapeutics Reports Phase 2 Data Showing TTI-101 Reduces Fibrosis in IPF Patients

    Tvardi Therapeutics Inc. has reported updates from its Phase 2 REVERT IPF clinical trial for TTI-101, an oral STAT3 inhibitor, in idiopathic pulmonary fibrosis (IPF) patients. Despite not meeting primary endpoints in October 2025, data from 40 patients show a 9.4% reduction in fibrosis score with TTI-101 compared to 2.4% in the placebo group. Additionally, 63% of TTI-101 patients had increased forced vital capacity (FVC) at 12 weeks, versus 46% in the placebo group. The company anticipates topline data from a Phase 1 study of TTI-109 in early 2026.

    Reuters·
    US
    TVRD
    +4.79%
    Reuters·
    US
    TVRD
    +4.79%

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    In Wednesday's pre-market session, several health care stocks saw significant movements. Specimen (ISPC) rose 20.4% to $0.36, while Vanda Pharmaceuticals (VNDA) increased 19.34% to $8.39. Other gainers included Inspire Veterinary (IVP) up 18.39% to $0.06, BioAtla (BCAB) up 14.58% to $0.82, and OSR Holdings (OSRH) up 8.58% to $0.63. Conversely, Profusa (PFSA) fell 14.3% to $0.1, Tvardi Therapeutics (TVRD) dropped 11.12% to $3.76, and Akari Therapeutics (AKTX) declined 11.07% to $0.24.

    benzinga_article·
    US
    PFSA
    +6.39%
    US
    VNDA
    +4.70%
    US
    BCAB
    +10.78%
    benzinga_article·
    US
    PFSA
    +6.39%
    US
    VNDA
    +4.70%
    US
    BCAB
    +10.78%
    © 2026 Longbridge｜Disclaimer